Enhertu Market Explained: What Is Fueling Growth To $ Billion By 2030?
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Enhertu Market Growth Potential: How Will Market Size Shift Through 2030?
The historical expansion was driven by a growing incidence of her2 positive cancers, the shortcomings of conventional chemotherapy, the initial achievements of targeted therapies, progress in molecular diagnostics, and an increasing number of oncology drug approvals.
The projected growth during the forecast period can be attributed to several factors, including the expanding applications for antibody drug conjugates, an increase in her2 testing adoption, a rising demand for precision cancer therapies, substantial oncology research funding, and positive clinical trial outcomes. Prominent trends expected in this period involve antibody drug conjugate cancer therapies, specific her2-directed treatments, the broadening scope of precision oncology, a greater utilization of biomarker-based cancer care, and a general shift towards advanced line targeted therapies.
Get A Free Sample Report With In-Depth Market Insights:
Enhertu Market Growth Drivers: What’s Behind The Acceleration?
The rising incidence of breast cancer is anticipated to fuel the expansion of the enhertu market. Breast cancer originates in breast cells, frequently within milk ducts or lobules, and can spread throughout the body. This growing prevalence is attributable to several factors, including an aging population, genetic predispositions, lifestyle choices like poor diet and insufficient physical activity, environmental exposures, and advancements in detection and screening methods. Enhertu delivers targeted therapy for breast cancer patients through a potent combination of chemotherapy and HER2-targeted treatment, thereby helping to enhance outcomes for individuals with advanced or metastatic HER2-positive breast cancer. For example, Breast Cancer Now, a UK-based charity, stated in September 2023 that approximately 600,000 people in the UK are currently living with a breast cancer diagnosis, a number projected to double to 1.2 million by 2030. Hence, the increasing prevalence of breast cancer is a significant driver for the enhertu market.
Enhertu Market Segments: Where Is Growth Concentrated?
The enhertu market covered in this report is segmented –
1) By Indication: HER2-Positive Metastatic Breast Cancer, HER2-Low Metastatic Breast Cancer, HER2-Mutant Non-Small Cell Lung Cancer (NSCLC), HER2-Positive Metastatic Gastric Cancer
2) By Treatment Line: First-Line Therapy, Second-Line Therapy, Third-Line Therapy
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies
Enhertu Market Trends: What’s Defining The Industry’s Next Phase?
A primary trend in the Enhertu market involves conducting clinical trials to expand its indications for treating various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer, beyond its established use in HER2-positive breast cancer. These ongoing clinical trials support the development of Enhertu as a targeted therapeutic option, demonstrating statistically significant and clinically meaningful improvements in progression-free survival for HR-positive, HER2-low metastatic breast cancer patients in the DESTINY-Breast06 Phase 3 trial, following one or more lines of endocrine therapy. For example, in April 2024, Daiichi Sankyo, a Japan-based pharmaceutical company, and AstraZeneca plc, a UK-based pharmaceutical company, announced the results of the DESTINY-Breast06 Phase 3 trial for ENHERTU (trastuzumab deruxtecan). The trial showed that ENHERTU significantly improves progression-free survival (PFS) in patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer who have received one or more lines of endocrine therapy. This study is notable because it is the first time a HER2-directed therapy has demonstrated a clinically meaningful benefit for this specific patient population.
Enhertu Market Key Participants And Competitive Landscape
Major companies operating in the enhertu market are AstraZeneca Plc, Daiichi Sankyo Co. Ltd.
View The Full Enhertu Market Report:
Enhertu Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the enhertu market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enhertu market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
